$CXW

CoreCivic (NYSE: CXW) investor lines up 2026 stock sale

CoreCivic (CXW) received a notice from Daren Swenson for a proposed sale of 20,000 shares, valued at $689,000, via UBS. The shares were acquired under an Employee Stock Plan in 2025, with the sale planned for 2026.

Original reporting
Published Sep 10, 2026, 7:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CXW
Neutral
low confidence
Mentioned
$CXW
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CXWNeutralLow
01

Why it matters

The filing is a routine disclosure with limited price relevance; investors may note the sale but unlikely to act.

02

Market read

Low relevance; small insider sale does not materially affect market perception.

03

What to watch

Potential future dilution if more insiders sell; monitor subsequent filings.

Relevance 4/10Novelty 3/10Timing: sale scheduled for Sep 11, 2026

Background

CoreCivic filed a Rule 144 notice for a planned sale of 20,000 shares by a holder, brokered by UBS.

Company-level read

Ticker impact

$CXWNeutralLow confidence
Context

Form 144 filing discloses sale of 20,000 CoreCivic shares worth $689,000 on Sep 11, 2026.

Expected impact

negligible effect on CXW price

Evidence & confidence

Sale size is modest ($689k) and represents a tiny fraction of total shares outstanding.

Market effects

None; CoreCivic operates in private corrections, not a sector driver.

No regional effect.

Minimal.

Counterpoint

Even small insider sales can signal confidence issues, but size is too low to infer.

Key entities

  • CoreCivic, Inc.

    Public prison operator (NYSE: CXW).

  • UBS Financial Services Inc.

    Acting as attorney‑in‑fact for the seller.

Related articles

$CXWHighAI 9/10

CoreCivic Soars as Massive ICE Funding Sparks Rally

CoreCivic (CXW) shares rose due to a $75 billion federal funding package for ICE and border security through 2029. Investors expect higher detention contracts and revenue. The company's real estate monetization and long-term contracts provide stability, but risks include policy changes and weak cash flow conversion.

$CXWMed

CoreCivic Inc stock hits 52-week high at $34.88

CoreCivic Inc. (CXW) stock reached a 52-week high of $34.88, with a 70.29% increase over the past year. The company reported Q2 2026 earnings of $0.38 per share, surpassing estimates, and announced a $500M share repurchase agreement. According to InvestingPro, the stock appears overvalued but has a low PEG ratio of 0.84.

$CXWHigh

Financial Outperformance and Demand Tailwinds Lead to Bullish Narrative Around CoreCivic (CXW)

Noble Capital reiterated its Outperform rating on CoreCivic (CXW), raising its target price to $42 from $35, citing strong Q2 results. The company reported $684.9M revenue, up 27.3% YoY, and adjusted EBITDA of $109.4M, up 5.9% YoY. CoreCivic also secured a new ICE contract and plans share buybacks and debt reduction. Risks include policy changes and revenue concentration.

$GEOHighAI 8/10

GEO Group And CoreCivic Stocks Are Getting Beaten Up Today – Why Such A Selloff?

GEO Group (GEO) and CoreCivic (CXW) shares fell after a Bloomberg report indicated ICE plans to reduce its network of private detention facilities to 34 government-owned locations. ICE contracts account for nearly half of GEO's projected 2026 revenue ($2.9B-$3.1B) and 40% of CoreCivic's Q4 revenue. Despite the reduction, private companies may still provide services like medical care and security.

$CXWMedAI 8/10

CoreCivic (CXW) Lifted Its 2026 Guidance, Is The Stock Still Undervalued?

CoreCivic (CXW) raised its 2026 guidance, expecting net income of $1.492B-$1.511B and EPS of $15.62-$15.82. The stock has seen significant gains, with a 3-year return of 209.08%, but recent momentum has eased. Analysts debate its valuation, with some seeing it as 19.2% undervalued at $31.99 per share, while others point to a high P/E ratio of 24.7x.